Study identifier:D1511M00004
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A randomised, double-blind, placebo-controlled, two-way crossover, single-centre methodologhy study in healthy subjects to evaluate the effect of oral dosing with AZD8309 on cells and inflammatory biomarkers in nasal lavage and blood after nasal challenge with lipopolysaccharide (LPS).
Healthy
N/A
Yes
AZD8309
All
20
Interventional
18 Years - 50 Years
Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verified 01 Oct 2009 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 AZD8309 | Drug: AZD8309 oral solution 30 mg/g, dose: 300mg bid for 3 days |
Placebo Comparator: 2 Placebo | Drug: AZD8309 oral solution 30 mg/g, dose: 300mg bid for 3 days |